1 min read
Add as a preferred source on Google

Stifel Upgrades Tandem to Buy and Downgrades Insulet on Pump Trends

Stifel linked both rating moves to survey results indicating recent trends in tubeless insulin pumps.

A compact insulin pump and a tubeless pod sit side by side / TokenPost.ai
A compact insulin pump and a tubeless pod sit side by side / TokenPost.ai

Stifel upgraded Tandem Diabetes Care (TNDM) to Buy from Hold and downgraded Insulet Corporation (PODD), linking the moves to survey results indicating recent trends in the tubeless insulin-pump market.

The rating actions came after the U.S. Food and Drug Administration (FDA) cleared a tubeless version of Tandem’s Mobi insulin-delivery system.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…